Metabolic and lipidomic characterization of malignant pleural effusion in human lung cancer

Yang, Zhiyi; Song, Zhengbo; Chen, Zhongjian; Guo, Zhenyu; Jin, Hangbiao; Ding, Cheng; Hong, Yanjun; Cai, Zongwei

doi:10.1016/j.jpba.2019.113069

Cited by 32 publications

(33 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are clear understanding on the heightened choline metabolism in cancer cells and tissues that support the progression, invasion and metastasis of cancer cells (9)(10)(11)(12)(13)(14)(15)(16)(17). In other way, cancer cells are known to divert the dietary source including choline to support the metabolic needs of breast carcinoma and other cancer cell types (11)(12)(13)(14)(15)(16).…”

Section: Level Of Choline and Phosphorylcholine In Nailsmentioning

confidence: 99%

“…There are preclinical and clinical findings that support the high abundance of cellular choline and choline based metabolism in cancer cells. On the other hand, membrane bound PC, lyso-PC and phosphorylcholine are reduced in the extracellular fluids including plasma (12)(13)(14)(15)(16)(17)(18)(19)(20)(21). In essence, distinct lipid metabolite pools at intracellular and extracellular levels are suggested to be a concerted efforts between cancer cells and associated tumor microenvironment that support abundance of various lipid metabolizing enzymes that modulate the metabolite profile as pro-tumor (11)(12)(13)(14)(15).…”

Section: Level Of Choline and Phosphorylcholine In Nailsmentioning

confidence: 99%

“…Cancer cells are equipped with metabolic machinery to remodel the lipid profiles in the intracellular and extracellular compartments that favors the pro-tumor microenvironment (13)(14)(15)(16)(17)(18)(19)(20)(21). There are significant findings that indicate the healthy human plasma has abundance of lysophophatidylcholine (LysoPC) that is required for the various physiological needs (13)(14)(15)(16)(17)(18)(19)(20)(21).…”

Section: Undetectable Level Of Lyso-pc In Nails Of Breast Cancer Patimentioning

confidence: 99%

“…The importance of metabolic heterogeneity is seen as one of key factors that contribute towards biomarkers development in breast cancer patients (5)(6)(7)(8)(9)(10)(11). Metabolic heterogeneity encompasses various metabolic adaptations including lipid remodeling by breast cancer cells to suffice the metabolic requirements in the tumor microenvironment (9)(10)(11)(12)(13)(14)(15)(16)(17). Therefore, appreciable attempts were made to determine lipid profiles mostly in blood, as it is the viable option to detect early and late stage physiological and pathological changes in breast cancer patients (10)(11)(12)(13)(14)(15)(16)(17).…”

Section: Introductionmentioning

confidence: 99%

“…Among key lipid metabolites, levels of choline derived lipids such as phosphatidylcholine (PC), phosphorylcholine and lyso-PC are suggested to decrease in breast cancer and other cancer types and these metabolites are seen as potential biomarkers (13)(14)(18)(19)(20)(21). In the current approach of lipid metabolomics, LC-HRMS, GC-MS and NMR spectroscopy were widely employed on whole metabolite extracts from blood and other biological fluid samples (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Novel approach reveals lipid metabolite reduction in nails of breast cancer patients as potential biomarker

Mitruka

Gore

Kumar

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND: Molecular adaptations in intracellular and extracellular microenvironment of breast cancer cells promote pro-tumor metabolic reprogramming. Hence, metabolic reprogramming is seen as a crucial factor in various tumor hallmarks including drug resistance, invasiveness and metastasis. Among well-known metabolic features of breast carcinoma including Warburg effects, altered amino acid metabolism, lipid remodeling is considered as key factors in achieving pro-tumor microenvironment. Therefore, a better understanding on molecular aspects of lipid remodeling is highly appreciated that may contribute towards future therapeutics and diagnostics purpose including the need of potential biomarkers. The identification and validation of lipid biomarkers are reported in the literature, but evidence on lipid metabolites as biomarkers in nails of breast cancer patients is completely unexplored. METHODS: This study reported a novel and specifically designed vertical tube gel electrophoresis (VTGE) system to assist in the purification of metabolites in the range of (~100-1000 Da) from nail samples. Fingernail clippings of breast cancer patients (N=10), and healthy subjects (N-12) were used for extraction and purification of metabolites. The VTGE system uses 15% polyacrylamide under non-denaturing and non-reducing conditions that makes eluted metabolites directly compatible with LC-HRMS and other analytical techniques. The characterization of lipid metabolites in nail lysates was done by positive ESI mode of Agilent LC-HRMS platform. RESULTS: Data suggest a novel observation that healthy and breast cancer patients show distinct accumulation of lipid metabolites specifically choline-based lipids. This is a first report that suggests that levels of choline, phosphorylcholine and lyso-PC are highly reduced and undetectable in nails of breast cancer patients over healthy subject. Furthermore, the potential use of reduced level of choline, phosphorylcholine and lyso-PC in nails of breast cancer patients is in line with current notion that these lipids are diverted to meet the pro-tumor activities in the tumor microenvironment. CONCLUSION: Data strongly provide a proof of concept for the potential use of lipid metabolites including choline, phosphorylcholine and lyso-PC as a set of biomarkers in nails of breast cancer patients. However, the authors propose that validity of these lipid biomarkers may be extended to large population size of breast cancer patients for future applications in early detection, grading, staging, predicting prognosis and therapeutic targeting of breast carcinoma.

show abstract

Section: Level Of Choline and Phosphorylcholine In Nailsmentioning

confidence: 99%

Section: Level Of Choline and Phosphorylcholine In Nailsmentioning

confidence: 99%

Section: Undetectable Level Of Lyso-pc In Nails Of Breast Cancer Patimentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Novel approach reveals lipid metabolite reduction in nails of breast cancer patients as potential biomarker

Mitruka

Gore

Kumar

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Applications of Lipidomics in Tumor Diagnosis and Therapy

Wang

2021

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Integration of clinical phenoms and metabolomics facilitates precision medicine for lung cancer

Yan,

Liu,

Song

et al. 2024

Cell Biol Toxicol

View full text Add to dashboard Cite

Lung cancer is a common malignancy that is frequently associated with systemic metabolic disorders. Early detection is pivotal to survival improvement. Although blood biomarkers have been used in its early diagnosis, missed diagnosis and misdiagnosis still exist due to the heterogeneity of lung cancer. Integration of multiple biomarkers or trans-omics results can improve the accuracy and reliability for lung cancer diagnosis. As metabolic reprogramming is a hallmark of lung cancer, metabolites, specifically lipids might be useful for lung cancer detection, yet systematic characterizations of metabolites in lung cancer are still incipient. The present study profiled the polar metabolome and lipidome in the plasma of lung cancer patients to construct an inclusive metabolomic atlas of lung cancer. A comprehensive analysis of lung cancer was also conducted combining metabolomics with clinical phenotypes. Furthermore, the differences in plasma lipid metabolites were compared and analyzed among different lung cancer subtypes. Alcohols, amides, and peptide metabolites were significantly increased in lung cancer, while carboxylic acids, hydrocarbons, and fatty acids were remarkably decreased. Lipid profiling revealed a significant increase in plasma levels of CER, PE, SM, and TAG in individuals with lung cancer as compared to those in healthy controls. Correlation analysis confirmed the association between a panel of metabolites and TAGs. Clinical trans-omics studies elucidated the complex correlations between lipidomic data and clinical phenotypes. The present study emphasized the clinical importance of lipidomics in lung cancer, which involves the correlation between metabolites and the expressions of other omics, ultimately influencing clinical phenotypes. This novel trans-omics network approach would facilitate the development of precision therapy for lung cancer. Graphical Abstract 1. Integrating multiple biomarkers or trans-omics results improves diagnostic accuracy and reliability in heterogeneous lung cancer. 2. Metabolomics and lipidomics, along with clinical phenotypes, construct a comprehensive metabolic profile of lung cancer patients. 3. TAG expression shows strong positive correlation with polar metabolites, potentially impacting clinical phenotypic changes in lung cancer patients.

show abstract

Metabolic and lipidomic characterization of malignant pleural effusion in human lung cancer

Cited by 32 publications

References 44 publications

Novel approach reveals lipid metabolite reduction in nails of breast cancer patients as potential biomarker

Novel approach reveals lipid metabolite reduction in nails of breast cancer patients as potential biomarker

Applications of Lipidomics in Tumor Diagnosis and Therapy

Integration of clinical phenoms and metabolomics facilitates precision medicine for lung cancer

Contact Info

Product

Resources

About